JP2020505044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505044A5 JP2020505044A5 JP2019540095A JP2019540095A JP2020505044A5 JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5 JP 2019540095 A JP2019540095 A JP 2019540095A JP 2019540095 A JP2019540095 A JP 2019540095A JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- genetically modified
- protein
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173206A JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450917P | 2017-01-26 | 2017-01-26 | |
| US62/450,917 | 2017-01-26 | ||
| PCT/US2018/015180 WO2018140573A1 (en) | 2017-01-26 | 2018-01-25 | B-cell engineering |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Division JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505044A JP2020505044A (ja) | 2020-02-20 |
| JP2020505044A5 true JP2020505044A5 (enExample) | 2020-12-17 |
Family
ID=62979713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540095A Withdrawn JP2020505044A (ja) | 2017-01-26 | 2018-01-25 | Ｂ細胞操作 |
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190352614A1 (enExample) |
| EP (1) | EP3573464A4 (enExample) |
| JP (2) | JP2020505044A (enExample) |
| KR (1) | KR20190111063A (enExample) |
| CN (1) | CN110536963A (enExample) |
| AU (1) | AU2018212652B2 (enExample) |
| BR (1) | BR112019015355A2 (enExample) |
| CA (1) | CA3051113A1 (enExample) |
| IL (1) | IL268110B2 (enExample) |
| MX (1) | MX2019008844A (enExample) |
| WO (1) | WO2018140573A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CA3051113A1 (en) * | 2017-01-26 | 2018-08-02 | Sangamo Therapeutics, Inc. | B-cell engineering |
| CA3056609A1 (en) | 2017-03-16 | 2018-09-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins |
| SG11202003907WA (en) | 2017-12-14 | 2020-05-28 | Flodesign Sonics Inc | Acoustic transducer drive and controller |
| BR112021007301A2 (pt) | 2018-10-18 | 2021-07-27 | Intellia Therapeutics, Inc. | composições e métodos para expressar fator ix |
| EP4070855B1 (en) * | 2019-11-01 | 2025-12-24 | Kyoto Prefectural Public University Corporation | B-cell antibody receptor and use thereof |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| WO2023192936A2 (en) * | 2022-03-30 | 2023-10-05 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| WO2024151683A2 (en) * | 2023-01-09 | 2024-07-18 | Walking Fish Therapeutics, Inc. | HUMAN B CELL ENGINEERED TO EXPRESS IgA AND IgM ANTIBODIES FOR THERAPEUTIC USE |
| EP4680727A2 (en) * | 2023-03-17 | 2026-01-21 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
| EP4698191A2 (en) * | 2023-04-17 | 2026-02-25 | Be Biopharma, Inc. | Engineered cell preparations for treatment of niemann pick b disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901511A0 (en) * | 2003-03-28 | 2003-04-17 | Bionomics Limited | Nucleic acid molecules associated with angiogenesis II |
| DK1804839T3 (da) * | 2004-09-22 | 2012-04-10 | St Jude Childrens Res Hospital | Forbedret ekspression af faktor ix i genterapivektorer |
| CA2756833C (en) * | 2009-04-09 | 2019-11-19 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
| EP3730615A3 (en) * | 2013-05-15 | 2020-12-09 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
| US9757420B2 (en) * | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
| HUE055583T2 (hu) * | 2014-09-16 | 2021-12-28 | Sangamo Therapeutics Inc | Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben |
| EP4177336A1 (en) * | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| WO2016161446A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| HRP20240338T1 (hr) * | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| CN108024544B (zh) * | 2015-07-13 | 2022-04-29 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的基因组工程化的递送方法及组合物 |
| AU2017207818B2 (en) * | 2016-01-15 | 2024-03-28 | Regents Of The University Of Minnesota | Methods and compositions for the treatment of neurologic disease |
| CA3051113A1 (en) * | 2017-01-26 | 2018-08-02 | Sangamo Therapeutics, Inc. | B-cell engineering |
| BR112019021094A2 (pt) * | 2017-04-10 | 2020-05-12 | Immatics Biotechnologies Gmbh | Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres |
| AU2018283310B2 (en) * | 2017-06-16 | 2025-02-13 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| CA3071683A1 (en) * | 2017-08-08 | 2019-02-14 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
| BR112020008568A2 (pt) * | 2017-11-09 | 2020-10-06 | Sangamo Therapeutics, Inc. | modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish) |
| WO2019149743A1 (en) * | 2018-01-30 | 2019-08-08 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| AU2019327913A1 (en) * | 2018-08-29 | 2021-03-18 | Nanjing Legend Biotech Co., Ltd. | Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof |
| EP3887395A4 (en) * | 2018-11-30 | 2022-07-27 | Intima Bioscience, Inc. | METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES |
-
2018
- 2018-01-25 CA CA3051113A patent/CA3051113A1/en active Pending
- 2018-01-25 US US16/480,939 patent/US20190352614A1/en not_active Abandoned
- 2018-01-25 MX MX2019008844A patent/MX2019008844A/es unknown
- 2018-01-25 EP EP18744407.0A patent/EP3573464A4/en not_active Withdrawn
- 2018-01-25 IL IL268110A patent/IL268110B2/en unknown
- 2018-01-25 BR BR112019015355A patent/BR112019015355A2/pt not_active IP Right Cessation
- 2018-01-25 CN CN201880021264.1A patent/CN110536963A/zh active Pending
- 2018-01-25 KR KR1020197023790A patent/KR20190111063A/ko not_active Ceased
- 2018-01-25 WO PCT/US2018/015180 patent/WO2018140573A1/en not_active Ceased
- 2018-01-25 JP JP2019540095A patent/JP2020505044A/ja not_active Withdrawn
- 2018-01-25 AU AU2018212652A patent/AU2018212652B2/en not_active Ceased
-
2022
- 2022-10-28 JP JP2022173206A patent/JP2022191524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wienert et al. | Wake-up sleepy gene: reactivating fetal globin for β-hemoglobinopathies | |
| Staal et al. | Autologous stem-cell-based gene therapy for inherited disorders: state of the art and perspectives | |
| Xi et al. | Genetically engineered pigs for xenotransplantation: Hopes and challenges | |
| JP2020500162A5 (enExample) | ||
| JP2016539627A5 (enExample) | ||
| De Ciuceis et al. | Immune mechanisms in hypertension | |
| Amelio et al. | p63 the guardian of human reproduction | |
| Kohn | Gene therapy for blood diseases | |
| JP2017504354A5 (enExample) | ||
| US12385070B2 (en) | Homology directed repair compositions for the treatment of hemoglobinopathies | |
| JP2021505187A (ja) | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 | |
| Paladini et al. | The multifaceted nature of aminopeptidases ERAP1, ERAP2, and LNPEP: from evolution to disease | |
| Naeimi Kararoudi et al. | Clustered regularly interspaced short palindromic repeats/Cas9 gene editing technique in xenotransplantation | |
| Bueren et al. | Advances in the gene therapy of monogenic blood cell diseases | |
| ES3032739T3 (en) | Genetically engineered hematopoietic stem cell as a platform for systemic protein expression | |
| JP2021513338A5 (enExample) | ||
| Patel et al. | The immune response to the fVIII gene therapy in preclinical models | |
| Crossley et al. | Effective therapies for sickle cell disease: are we there yet? | |
| Kyriakopoulou et al. | Gene editing innovations and their applications in cardiomyopathy research | |
| Ly et al. | Gene therapy in the treatment of heart failure | |
| EP3765617A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
| Březina et al. | Mechanisms of direct and indirect presentation of self-antigens in the thymus | |
| Naldini et al. | The EHA research roadmap: hematopoietic stem cell gene therapy | |
| Wu et al. | Multiple gene modifications of pigs for overcoming obstacles of xenotransplantation | |
| Barbarani et al. | β-Hemoglobinopathies: the test bench for genome editing-based therapeutic strategies |